At a glance
- Originator Aegis Therapeutics
- Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
- Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acromegaly; Diarrhoea
Most Recent Events
- 22 Sep 2016 Aegis Therapeutics has patent protection for octreotide (intranasal) in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acromegaly in USA (Intranasal, Spray)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acromegaly in USA (PO)